The licensing agreement entails that Avernus will be the exclusive distributor of BupiZenge in the GCC region, including Bahrain, Kuwait, Oman, Qatar, Saudi Arabia, and the UAE, pending successful completion of the BupiZenge phase 3 trial and subsequent approval from the Gulf Central Committee for Drug Registration (GCC-DR).  
 
OncoZenge continues to seek partnerships for licensing and distribution of BupiZenge in all key markets globally that may launch based on the anticipated successful completion of the phase 3 trial and subsequent regulatory approval, in Europe, it states.

As part of the agreement, OncoZenge will provide the necessary support to Avernus for regulatory filings in the GCC, and establish volume supply of BupiZenge. Avernus will invest in regulatory efforts towards GCC market approvals, and the marketing and distribution capabilities needed for launch and successful adoption. Commercial milestones of up to USD 130,000 will be paid by Avernus upon 1st market approval in a GCC country and reaching certain commercial milestones.

“This partnership with Avernus is a key step in our goal to bring BupiZenge to patients in the GCC and globally. Avernus has a strong reputation in the local pharmaceutical market, and they are the ideal partner to successfully introduce the product in the region,” says Stian Kildal, CEO of OncoZenge.